A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities

This study is testing a treatment approach for newly diagnosed multiple myeloma patients who have a specific high-risk genetic abnormality — a problem with the TP53 gene — that makes standard treatments less effective. The approach combines standard drug therapy (VRd), CAR-T cell therapy, and stem cell transplant. **You may be eligible if...** - You are between 18 and 65 years old - You have a newly confirmed diagnosis of multiple myeloma - Your myeloma has TP53 abnormalities (a specific genetic change found in cancer cells) - You have not yet received any treatment for multiple myeloma **You may NOT be eligible if...** - You have already received chemotherapy or other anti-myeloma treatments - You have significant heart, liver, or lung problems - You have active serious infections - You are pregnant or breastfeeding - You have another active cancer Talk to your doctor to see if this trial is right for you.